Metformin and resveratrol are AMPK activators and their potential for AD therapy has been assessed in AD mouse models such as APP/PS1 mice (Chen et al., 2021; Vingtdeux et al., 2010; Zhao et al., 2023). This evidence concerns the gene PSEN1 and Alzheimer disease.